Tirzepatide + Retatrutide
Also known as: Tirz + Reta, Dual-agonist + triple-agonist blend
Pre-mixed metabolic blend combining tirzepatide, a GIP/GLP-1 dual receptor agonist, with retatrutide, an investigational GIP/GLP-1/glucagon triple receptor agonist, both acting on incretin pathways to reduce appetite and improve glucose handling and weight. Tirzepatide is FDA-approved as a finished prescription drug (Mounjaro/Zepbound) but combining it with retatrutide is not an approved use; retatrutide remains investigational in Phase 3 (Eli Lilly TRIUMPH, NDA anticipated late 2026). This specific blend is not an approved product and has no published controlled human efficacy or safety data — any rationale is inferred from the separate agents, and combination-specific human data is lacking.
Who's worth your money for Tirzepatide + Retatrutide
Every current seller, ranked by independent evidence — Merit Score, latest COA purity, and live $/mg (size-normalized). Prices refresh daily. Rankings are never paid.
No sellers for Tirzepatide + Retatrutide are indexed yet — we add vendors and their prices as we find them.
Watch Tirzepatide + Retatrutide
Get one email when the market actually moves — no newsletter, no noise.
About Tirzepatide + Retatrutide
CAS
—
Molecular formula
—
Typical dose range
No validated or approved blend protocol exists, and overlapping incretin agonism makes stacking redundant and higher-risk. Component references: tirzepatide 2.5–15 mg once weekly subcutaneous (approved titration); retatrutide ~2–12 mg once weekly subcutaneous in trials. Research use only.
Half-life
Component-dependent and not characterized for the mixture. Tirzepatide: ~5 days, supporting once-weekly dosing; retatrutide is likewise engineered for once-weekly dosing.
Common research uses
Safety notes
Not FDA-approved as a blend; only tirzepatide is approved as a standalone prescription product, while retatrutide is investigational and research/grey-market when sold loose. Combining two incretin agonists with overlapping GIP/GLP-1 activity offers no established benefit and can compound dose-dependent GI effects (nausea, vomiting, diarrhea) plus risks such as pancreatitis and gallbladder disease; retatrutide's glucagon agonism adds further effects under study. No combination-specific human safety data exists.
Reconstitution
Grey-market versions may be supplied lyophilized; reconstitute with bacteriostatic water and refrigerate. As an unapproved blend (including any compounded or research-sourced tirzepatide), dose accuracy, sterility and content are not assured.
COAs for Tirzepatide + Retatrutide
2 third-party tests across 1 vendor. Each card links to the full report.
15 citations indexed for Tirzepatide + Retatrutide
Study · 2026
Incretin-Based Dual and Triple Agonists in Overweight or Obese Individuals: A Systematic Review and Meta-Analysis
Incretin-based dual and triple agonists have emerged as effective options for obesity management, offering enhanced weight loss through multi-receptor agonism. However, data on their efficacy and safety remain limited.
Study · 2026
Beyond weight loss: Preserving muscle health in the incretin era
review · 2026
Evolution of incretin-based therapies: From GLP-1 monotherapy to dual and triple agonists: A new era in metabolic therapy
Incretin-based therapies have revolutionised the management of metabolic disorders, transitioning from DPP-4 inhibitors to advanced GLP-1 receptor agonists (GLP-1RAs) and next-generation dual and triple agonists.
Study · 2026
Trends in glucagon-like peptide-1 receptor agonist utilization and expenditure in Croatia
IntroductionGlucagon-like peptide-1 receptor agonists (GLP-1 RAs) have transformed the management of type 2 diabetes and obesity by improving glycemic control, promoting weight loss, and reducing cardiovascular risk.
review · 2026
Unregulated Peptide Use in the Age of Biohacking: Digital Promotion, Gray-Market Access, and Emerging Public Health Risks
Unregulated peptide use is emerging as a digitally mediated public health concern.
review · 2026
Anti-obesity medications and cognitive disorder risk: a discrepancy between RCTs and real-world evidence
Objectives To investigate the association between anti-obesity medication (AOM) use and the risk of cognitive disorder in individuals with overweight and obesity.
Research use only. Not for human consumption and not approved by the FDA. Nothing here is medical advice.